Company Overview
Camp4 Therapeutics Corporation operates as a clinical-stage biopharmaceutical entity dedicated to discovering and developing RNA-based therapeutics designed to treat various genetic diseases. The company functions within the healthcare sector and specifically the biotechnology industry, an environment characterized by high-risk research and development cycles and significant capital requirements for bringing novel treatments to market. With a market capitalization of $246.62M and an annual revenue of $3.50M, the company maintains a relatively small operational footprint supported by a workforce of 48 employees. These financial figures indicate that the enterprise is a micro-cap biotechnology firm currently focused on early-stage product candidates rather than established commercialization, suggesting a strategic position that relies heavily on successful clinical outcomes to drive future value creation.
Financial Health
The company reported a revenue of $3.50M over the trailing twelve months, accompanied by a net income of $-80,403,000 and an EBITDA of $-50,422,000. The substantial gap between the modest revenue figure and the significant net loss reveals a cost structure dominated by heavy investment in research, development, and clinical trial expenses typical of clinical-stage biotechnology firms. Free cash flow stands at $-20,641,124, which indicates that the company is currently burning cash to fund its operations and development pipeline, thereby limiting its immediate financial flexibility without external financing or asset monetization. The company presents a gross margin of 0.0%, an operating margin of -3671.3%, and a profit margin of 0.0%, reflecting that operating costs vastly exceed revenue generation at this stage of development. On the balance sheet, the company holds $109.52M in cash against $2.00M in debt, resulting in a debt-to-equity ratio of 4.20, which suggests a leveraged capital structure where equity claims are diluted relative to debt obligations despite the lack of immediate debt service pressure. The current ratio is listed at 7.35, indicating a strong ability to cover short-term liabilities with current assets, although the absolute liquidity is offset by the rapid cash burn rate. Return on Equity is reported at -145.1% and return on assets at -33.2%, metrics that reveal management is currently generating negative returns on the capital base as it invests heavily in long-term product development rather than producing immediate shareholder value.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is reported as -6.72, implying that the market expects earnings to remain negative or for the company to require significant capital infusion before becoming profitable. The price-to-book ratio is 5.17, which indicates a significant market premium over the company's book value, a valuation metric common in biotechnology firms where intellectual property and future pipeline potential are priced higher than tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 70.50 and an EV/EBITDA of -2.76 suggest that investors are pricing the company based on revenue multiples rather than earnings power, reflecting high expectations for the success of its lead product candidates. The stock has traded between a 52-week high of $7.75 and a 52-week low of $1.30, and without a specific current price provided in the source data, the valuation is contextualized within this wide volatility range typical for small-cap biotech stocks with high beta characteristics. The beta is listed as N/A, meaning there is no specific historical volatility data available to compare the stock's price movements against the broader market in this dataset.
Growth & Income
Revenue growth year-over-year is reported as -46.6%, while earnings growth is N/A due to the absence of profitable earnings history, indicating that the company is not currently in a growth phase regarding profitability but rather in a development phase. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all generated cash and incurs losses to reinvest into its research and development efforts rather than distributing income to shareholders. The absence of a payout ratio further confirms that the company prioritizes funding its RNA-based therapeutic pipeline over returning capital to investors, a standard strategy for clinical-stage entities. Overall, the growth and income profile is defined by declining revenue and negative earnings, which is characteristic of a company in the early clinical trial stages of its lead product candidate CMP-001.